These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 37389706)

  • 1. Mirikizumab: First Approval.
    Keam SJ
    Drugs; 2023 Jul; 83(11):1045-1052. PubMed ID: 37389706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mirikizumab for the treatment of moderate to severe ulcerative colitis.
    Hanzel J; Ma C; Jairath V
    Immunotherapy; 2023 Oct; 15(15):1199-1208. PubMed ID: 37465925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mirikizumab Exposure-Response Relationships in Patients with Moderately-to-Severely Active Ulcerative Colitis in Randomized Phase II and III Studies.
    Friedrich S; Chua L; Adams DH; Crandall W; Zhang XC
    Clin Pharmacol Ther; 2024 Aug; 116(2):435-447. PubMed ID: 38797892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.
    Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Feagan BG; Hibi T; Tuttle JL; Klekotka P; Friedrich S; Durante M; Morgan-Cox M; Laskowski J; Schmitz J; D'Haens GR
    Gastroenterology; 2020 Feb; 158(3):537-549.e10. PubMed ID: 31493397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease.
    Sands BE; Peyrin-Biroulet L; Kierkus J; Higgins PDR; Fischer M; Jairath V; Hirai F; D'Haens G; Belin RM; Miller D; Gomez-Valderas E; Naegeli AN; Tuttle JL; Pollack PF; Sandborn WJ
    Gastroenterology; 2022 Feb; 162(2):495-508. PubMed ID: 34748774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vedolizumab: first global approval.
    Poole RM
    Drugs; 2014 Jul; 74(11):1293-303. PubMed ID: 24985716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23.
    Steere B; Beidler C; Martin A; Bright S; Kikly K; Benschop RJ
    J Pharmacol Exp Ther; 2023 Nov; 387(2):180-187. PubMed ID: 37714687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study.
    Steere B; Schmitz J; Powell N; Higgs R; Gottlieb K; Liu Y; Jia B; Tuttle JL; Sandborn WJ; Sands BE; D'Haens G; Reinisch W; Krishnan V
    Clin Transl Gastroenterol; 2023 Jul; 14(7):e00578. PubMed ID: 36881820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies.
    Chua L; Friedrich S; Zhang XC
    Clin Pharmacokinet; 2023 Oct; 62(10):1479-1491. PubMed ID: 37610533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
    D'Haens G; Dubinsky M; Kobayashi T; Irving PM; Howaldt S; Pokrotnieks J; Krueger K; Laskowski J; Li X; Lissoos T; Milata J; Morris N; Arora V; Milch C; Sandborn W; Sands BE;
    N Engl J Med; 2023 Jun; 388(26):2444-2455. PubMed ID: 37379135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mirikizumab: A New Therapeutic Option for the Treatment of Ulcerative Colitis.
    Choi D; Sheridan H; Bhat S
    Ann Pharmacother; 2024 Nov; 58(11):1134-1139. PubMed ID: 38344998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis.
    Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Hibi T; D'Haens GR; Tuttle JL; Krueger K; Friedrich S; Durante M; Arora V; Naegeli AN; Schmitz J; Feagan BG
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):105-115.e14. PubMed ID: 32950748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis.
    Dubinsky MC; Jairath V; Feagan BG; Naegeli AN; Tuttle J; Morris N; Shan M; Arora V; Lissoos T; Agada N; Hibi T; Sands BE
    BMJ Open Gastroenterol; 2023 Mar; 10(1):. PubMed ID: 37001911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes.
    Magro F; Pai RK; Kobayashi T; Jairath V; Rieder F; Redondo I; Lissoos T; Morris N; Shan M; Park M; Peyrin-Biroulet L
    J Crohns Colitis; 2023 Oct; 17(9):1457-1470. PubMed ID: 37057827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Questions and answers about the management of Crohn's disease and ulcerative colitis with vedolizumab.
    Hinojosa Del Val J; Barreiro-de Acosta M
    Gastroenterol Hepatol; 2019 Dec; 42(10):650-656. PubMed ID: 31635855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of mirikizumab for the treatment of ulcerative colitis.
    White C; Irving PM
    Expert Opin Biol Ther; 2024 Nov; 24(11):1199-1206. PubMed ID: 39360778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program.
    Sandborn WJ; Vermeire S; Tyrrell H; Hassanali A; Lacey S; Tole S; Tatro AR;
    Adv Ther; 2020 Jul; 37(7):3417-3431. PubMed ID: 32445184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, Denmark
    Gastroenterol Hepatol (N Y); 2019 May; 15(5 Suppl 2):1-24. PubMed ID: 31632213
    [No Abstract]   [Full Text] [Related]  

  • 19. Vedolizumab: An integrin-receptor antagonist for treatment of Crohn's disease and ulcerative colitis.
    Hahn L; Beggs A; Wahaib K; Kodali L; Kirkwood V
    Am J Health Syst Pharm; 2015 Aug; 72(15):1271-8. PubMed ID: 26195652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lebrikizumab: First Approval.
    Keam SJ
    Drugs; 2024 Mar; 84(3):347-353. PubMed ID: 38388870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.